Age, C-reactive protein, and hospital stay Are associated with switching from azithromycin to doxycycline in pediatric macrolide-resistant Mycoplasma pneumoniae pneumonia - Scorecard - DentalSpire

Age, C-reactive protein, and hospital stay Are associated with switching from azithromycin to doxycycline in pediatric macrolide-resistant Mycoplasma pneumoniae pneumonia

  • By

  • Mengzhen Zhang

  • Qirui Liu

  • Hao Wei

  • Ailian Wang

  • Jiaoyan Wang

  • Hai Li

  • Xueling Jing

  • April 30, 2026

  • 0 min

Share

Clinical Scorecard: Factors Influencing the Transition from Azithromycin to Doxycycline in Pediatric Patients with Macrolide-Resistant Mycoplasma pneumoniae Pneumonia

At a Glance

CategoryDetail
ConditionMacrolide-resistant Mycoplasma pneumoniae pneumonia
Key MechanismsResistance mediated by mutations in the 23S rRNA gene, particularly A2063G
Target PopulationChildren aged 29 days to 14 years with Mycoplasma pneumoniae pneumonia
Care SettingPediatric hospitals in Nanchong, China

Key Highlights

  • 91.3% macrolide resistance gene positivity rate observed in the study cohort
  • Increased age, elevated CRP, and prolonged hospital stay are predictors for switching antibiotics
  • Doxycycline is suggested as a first-line alternative for confirmed MRMP cases

Guideline-Based Recommendations

Diagnosis

  • Resistance gene testing should be performed for children with Mycoplasma pneumoniae pneumonia

Management

  • Consider switching from azithromycin to doxycycline in cases of confirmed macrolide resistance

Monitoring & Follow-up

  • Monitor inflammatory markers such as CRP and clinical parameters during hospitalization

Risks

  • Doxycycline use in children may lead to permanent tooth discoloration and enamel hypoplasia

Patient & Prescribing Data

Children diagnosed with Mycoplasma pneumoniae pneumonia

Clinical decisions should integrate biomarkers like CRP and age rather than relying solely on genetic results

Clinical Best Practices

  • Use targeted next-generation sequencing for accurate detection of resistance genes
  • Integrate clinical judgment with resistance gene testing results for antibiotic therapy decisions

References

Original Source(s)

Related Content